Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective MET kinase inhibitor

Tepotinib (Specialist drug)

Brand names: Tepmetko

Tepotinib is an oral MET inhibitor used in the treatment of advanced non-small-cell lung cancer harbouring MET exon 14 skipping alterations. It is a specialist drug initiated under oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits the MET receptor tyrosine kinase, blocking downstream signalling that drives proliferation and survival of MET-altered tumour cells.

Prescribing in practice

  • Interstitial lung disease and pneumonitis can occur and may be fatal, so new or worsening respiratory symptoms require prompt evaluation and treatment interruption.
  • Peripheral oedema is common and may necessitate dose modification, and hepatotoxicity can occur requiring monitoring of liver enzymes.
  • It requires confirmation of an eligible MET alteration by a validated test before initiation, and interacts with certain P-glycoprotein substrates and CYP3A modulators.

Monitoring

Monitor liver function and assess regularly for fluid retention and respiratory symptoms throughout treatment.

Counselling the patient

  • Report new cough, breathlessness or fever without delay.
  • Tell your team about swelling of the legs, ankles or face.
  • Do not stop or change the dose yourself; attend for your blood tests.

Evidence & guidelines

Tepotinib demonstrated durable responses in MET exon 14 skipping non-small-cell lung cancer in the VISION trial.

Reference: NICE TA789; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways